Evaxion Biotech A/S (EVAX) Stock Analysis & Winston Score

Evaxion Biotech is a Danish biotechnology company that uses artificial intelligence to design personalized vaccines. Its main focus is on cancer vaccines and infectious disease vaccines, targeting patients and eventually partnering with hospitals or pharmaceutical companies. The company's AI platform, called PIONEER, analyzes a patient's tumor to help create a vaccine tailored specifically to that individual. Evaxion makes money primarily through research grants, government contracts, and potential future licensing deals — it does not yet sell a commercial product. The company is based in Copenhagen, Denmark, and is small, with a market cap near zero and significant operating losses, reflecting its early-stage status. Its AI-driven approach to vaccine design is its main differentiator, but the biggest risk it faces is the long, expensive path through clinical trials needed before any product can reach patients and generate meaningful revenue.